The Dutch automated insulin delivery system developer said it began production of consumables, including infusion sets and insulin cartridges, with the Molex company — a leading global medical technology contract development and manufacturing organization (CDMO). The collaboration more than triples its consumables production capacity, with an initial scale to support more than 17,000 users.
ViCentra said its expanded supply positions it to add thousands of new users across Germany, the Netherlands and France in the second half of 2026. It said Germany represents the world’s second-largest insulin pump market. This increase in production and supply chain expansion positions the company to accelerate growth across Europe.
Phillips Medisize offers deep expertise in industrializing drug-delivery platforms, including insulin pumps and continuous glucose monitors (CGMs). ViCentra said the partnership brings scale and quality systems to its user-centered technology to support commercial growth.
The collaboration comes as ViCentra builds on a handful of milestones in its quest to bring Kaleido to more people with diabetes.
More about ViCentra and Kaleido
Kaleido is a miniature, patch-style insulin pump. ViCentra describes it as the smallest, lightest and most precise insulin patch pump in its class. The pump offers users options in terms of wearability and comes with two durable, rechargeable pumps, eliminating the need to dispose of the pump every three days, while the infusion set lasts for that three-day span. Rather than a traditional syringe pump setup, Kaleido has a micro pumping chamber that uses valves alongside a unique blockage detection system.
ViCentra hopes to stake its claim in a hot patch pump market, led by Insulet, with potential competitors, like MiniMed, Beta Bionics and Tandem Diabetes Care, are developing their own patch pumps. PharmaSens and SiBionics also recently unveiled their own entry, an all-in-one device, too.
Utrecht, The Netherlands-based ViCentra initially closed its Series D in September, bringing in $85 million. It then closed a $13 million extension to the financing to kick off 2026, bringing the total raised to $98 million. CEO Tom Arnold explained the company’s plans for a big commercial push with the funds in an interview with Drug Delivery Business News after the initial closing.
The company said it planned to use funds to scale manufacturing and deepen execution in Germany, the Netherlands and France. It also hopes to accelerate preparations to bring its next-generation Kaleido insulin patch pump to the U.S. market. It recently launched its Kaleido smartphone-controlled hybrid closed-loop insulin delivery system in Europe, pairing Kaleido with Diabeloop’s DBLG2 algorithm and the Dexcom G7 CGM.
Commentary from ViCentra and Phillips Medisize officials
Tom Arnold, ViCentra CEO, said:
“This is a very significant and crucial operational milestone for ViCentra. Tripling capacity and improving margin performance allow ViCentra to bring Kaleido to more people living with diabetes, reliably and at scale, across additional markets. With our new supply chain partner we now have the additional ability to continue to expand capacity.”
David Thoreson, VP of global operations at Phillips Medisize, said:
“ViCentra’s design‑led approach to wearable insulin delivery is exactly the type of innovation our global CDMO platform is built to industrialize. Our capabilities in high-volume precision molding, assembly and rigorous validation position us to support a dependable supply of Kaleido consumables across key European markets.”
